Eastman Chemical heads into its third-quarter report with a conflict between its outlook and its share price. Management told investors it expected earnings to approach $1.97 a share, well above where the Street sat at the time. Since then the stock has fallen about 9% while the S&P 500 gained more than 3%. Either the market doubts the company's best quarter in years can hold up, or it is pricing in second-half risks that management has so far played down. The report due after the close on October 29 should show which view is right.

Analysts now expect $1.93 a share on revenue of $2.39 billion. That would be a gain of roughly 69% from the $1.14 earned a year ago, on sales growth of about 8.5%. Consensus has moved up from $1.81 toward the guidance but still sits slightly below it. So the Street is giving management a small discount rather than taking the $1.97 figure at face value. The revenue estimate also implies a step down from the second quarter's $2.51 billion. That fits management's view that Chemical Intermediates spreads will narrow as Middle East supply conditions return to normal. Matching the second quarter's $1.97 on lower sales would itself say something about the mix.

The main question is whether the drivers behind last quarter's beat keep working. Advanced Materials volumes rose 5% from a year earlier. Management guided the third quarter flat sequentially but well ahead of last year, which is a big change from the destocking story of late 2025. Price versus cost has also turned from a headwind into a tailwind from the first half to the second, as mid-single-digit specialty price increases and sharp sequential increases in intermediates held. Margins that show those gains still in place, even as intermediates normalize, would support the guidance. If volumes in Advanced Materials hold but margins slip, the price-cost story would look shaky. The pull-forward of maintenance turnarounds into the third quarter also adds a cost drag, with the expected sequential benefit cut to roughly $10 million to $20 million.

The circular business is the longer-term test. Renew revenue topped $100 million in the first half, about double the prior year, and the Kingsport methanolysis plant has moved from roughly half utilization toward full capability. Management did trim the full-year circular outlook, citing recycled PET capacity limits and slower customer ramps. Signs that the new Triton capacity line, Europe's BPA ban and the new recyclable cosmetics product are turning into orders would ease that concern. Any further cut would raise doubts about the $200 million EBITDA target for the first plant. Fibers remains the weak spot, with the expected textiles benefit now gone after an earlier guidance cut.

Cash flow deserves more attention than usual. Operating cash flow guidance fell to about $900 million after receivables absorbed $370 million in the first half. A third quarter that starts to reverse that build would help answer worries about earnings quality. A further increase would give skeptics more support.

Sentiment has improved modestly, from slightly bearish before the last report to mildly bullish now, but the shares tell a more cautious story. At $63.50 the stock sits below its 200-day moving average of about $71. It is also only a few percent above its post-earnings low of $61.75, after failing to hold above the $75 area. That leaves the stock priced for disappointment. The verdict will likely depend on the fourth-quarter outlook. If management can show specialty pricing and volumes making up for fading intermediates spreads, the very strong earnings growth it promised still holds. If it cannot, the selloff will look like the market saw the peak first.